iShares US Pharmaceuticals ETF
122 hedge funds and large institutions have $125M invested in iShares US Pharmaceuticals ETF in 2022 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 29 increasing their positions, 31 reducing their positions, and 13 closing their positions.
92% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 13
20% more capital invested
Capital invested by funds: $104M → $125M (+$21.3M)
9% more funds holding
Funds holding: 112 → 122 (+10)
3.54% more ownership
Funds ownership: 78.21% → 81.75% (+3.5%)
6% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 31
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $233K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
+$5.41M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.83M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.69M |
| 4 |
Goldman Sachs
New York
|
+$1.58M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFA
Arlington Financial Advisors
Santa Barbara,
California
|
-$2.44M |
| 2 |
SPIA
Steward Partners Investment Advisory
New York
|
-$1.48M |
| 3 |
Morgan Stanley
New York
|
-$1.18M |
| 4 |
AWM
AE Wealth Management
Topeka,
Kansas
|
-$1.04M |
| 5 |
Fisher Asset Management
Camas,
Washington
|
-$891K |
IHE Hedge Fund Activity: Q1 2022 in Review
122 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2022, worth a combined $125M — up 20% from $104M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new IHE positions and 13 closed out — a net gain of 12 holders — while 29 added to existing stakes and 31 trimmed.
The largest buyer was RWA Wealth Partners, opening a new position worth an estimated $5.41M. The largest seller was Arlington Financial Advisors, exiting entirely with an estimated $2.44M sold.
- 122 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2022, up from 112 in Q4 2021.
- Funds reported $125M of iShares US Pharmaceuticals ETF stock for Q1 2022, up 20% quarter-over-quarter.
- 25 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2022 and 13 closed out, a net change of +12 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q1 2022 was RWA Wealth Partners, an estimated $5.41M added.
- The largest iShares US Pharmaceuticals ETF seller in Q1 2022 was Arlington Financial Advisors, an estimated $2.44M sold.
Based on aggregated 13F filings for Q1 2022.